Avantor, Inc.
AVTRMedical Instruments & Supplies
$16.05−3.78%As of Oct 30vs prior close
- Market cap
- $10.9B
- P/E (TTM)
- 32.1×
- P/E (FY1)
- 19.7×
- From 52W high
- −7.17%
- EPS (LTM)
- $0.50
- Revenue (LTM)
- $6.6B
- Net margin
- 5.08%
Nomior Score
52
Steady ProfileTop 46% of the scored universe
Growth26
Quality59
Value64
Momentum66
Resilience44
Growth
+23.04%revenue a year over 8 fiscal years
YE17 $1.2BLTM $6.6B
Connections
Revenue to profitQ3 YE26
12% of revenue became net profit, up 56 pts on a year.
Latest resultsThird Quarter 2026
- Revenue
- $1,698.3 million
- Net income
- $203.4 million
- Diluted EPS
- $0.30
- Adjusted EPS
- $0.22
Avantor returned to year-over-year sales growth in the third quarter, with VWR Distribution & Services accelerating and Bioscience & Medtech Products returning to organic growth. Net income rose sharply from the prior-year period, which included a large goodwill impairment, and free cash flow was robust, further strengthening the balance sheet. Management raised its full-year organic growth, adjusted EPS and free cash flow guidance.
Who owns it
2funds, 5 tracked portfolios